Finivi Inc. is experiencing institutional buying and selling of shares, concurrent with TD Cowen raising its price target to $300 and issuing a buy rating.
2 reports, 2 independent
Updated Sep 8
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Finivi Inc. is experiencing institutional buying and selling of shares, concurrent with TD Cowen raising its price target to $300 and issuing a buy rating.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Oracle Corporation
American multinational computer corporation
-
TD Cowen
American investment bank
Related events
- Datadog saw institutional investment changes tracked by the SEC and received a buy rating from TD Cowen.
- Analyst reports, price target changes, and a Form 8-K filing were reported alongside details of Thoma Bravo's ownership.
- Truist Financial set a $90.00 price target on Edwards Lifesciences shares, and TD Cowen reaffirmed its buy rating and raised the price objective.
- Truist Financial started coverage on Genmab shares, and TD Cowen raised rating and price target for the company, which trades on Nasdaq.
- Amundi purchased additional shares of Oracle Corporation stock on October 10, 2026.